全文获取类型
收费全文 | 902篇 |
免费 | 57篇 |
国内免费 | 10篇 |
专业分类
儿科学 | 20篇 |
妇产科学 | 17篇 |
基础医学 | 82篇 |
口腔科学 | 25篇 |
临床医学 | 84篇 |
内科学 | 186篇 |
皮肤病学 | 10篇 |
神经病学 | 12篇 |
特种医学 | 107篇 |
外科学 | 55篇 |
综合类 | 42篇 |
预防医学 | 40篇 |
眼科学 | 4篇 |
药学 | 17篇 |
肿瘤学 | 268篇 |
出版年
2023年 | 4篇 |
2021年 | 3篇 |
2020年 | 6篇 |
2019年 | 7篇 |
2018年 | 4篇 |
2017年 | 9篇 |
2016年 | 3篇 |
2015年 | 14篇 |
2014年 | 13篇 |
2013年 | 20篇 |
2012年 | 21篇 |
2011年 | 34篇 |
2010年 | 34篇 |
2009年 | 25篇 |
2008年 | 22篇 |
2007年 | 43篇 |
2006年 | 38篇 |
2005年 | 29篇 |
2004年 | 39篇 |
2003年 | 24篇 |
2002年 | 27篇 |
2001年 | 20篇 |
2000年 | 17篇 |
1999年 | 29篇 |
1998年 | 34篇 |
1997年 | 35篇 |
1996年 | 45篇 |
1995年 | 26篇 |
1994年 | 24篇 |
1993年 | 22篇 |
1992年 | 15篇 |
1991年 | 20篇 |
1990年 | 30篇 |
1989年 | 29篇 |
1988年 | 29篇 |
1987年 | 20篇 |
1986年 | 24篇 |
1985年 | 17篇 |
1984年 | 16篇 |
1983年 | 16篇 |
1982年 | 10篇 |
1981年 | 18篇 |
1980年 | 7篇 |
1978年 | 7篇 |
1977年 | 9篇 |
1976年 | 7篇 |
1975年 | 7篇 |
1974年 | 3篇 |
1973年 | 2篇 |
1972年 | 5篇 |
排序方式: 共有969条查询结果,搜索用时 203 毫秒
1.
2.
Repair of large midline incisional hernias with polypropylene mesh: Comparison of three operative techniques 总被引:9,自引:0,他引:9
de Vries Reilingh TS van Geldere D Langenhorst BLAM de Jong D van der Wilt GJ van Goor H Bleichrodt RP 《Hernia》2004,8(1):56-59
Polypropylene mesh is widely used for the reconstruction of incisional hernias that cannot be closed primarily. Several techniques have been advocated to implant the mesh. The objective of this study was to evaluate, retrospectively, early and late results of three different techniques, onlay, inlay, and underlay. The records of 53 consecutive patients with a large midline incisional hernia — 25 women and 28 men, mean age 60.4 (range 28–94) — were reviewed. Polypropylene mesh was implanted using the onlay technique in 13 patients, inlay in 23 patients, and underlay in 17 patients. Either the greater omentum or a polyglactin mesh was interponated between the mesh and the viscera. The records of these 53 patients were reviewed with respect to: size and cause of the hernia, pre- and postoperative mortality and morbidity, with special attention to wound complications. Patients were invited to attend the outpatient clinic at least 12 months after implantation of the mesh for physical examination of the abdominal wall. Postoperative complications occurred in 14 (26.4%) patients. The onlay technique had significantly more complications, as compared to both other techniques. Reherniation occurred in 15 (28.3%) patients. The reherniation rate of the inlay technique was significantly higher than after the underlay technique (44% vs 12%, P=0.03) and tended to be higher than the onlay technique (44% vs 23%, P=0.22). Repair of large midline incisional hernias with the use of a polypropylene mesh carries a high risk of complications and has a high reherniation rate. The underlay technique seems to be the better technique. 相似文献
3.
Nonheme iron in sickle erythrocyte membranes: association with phospholipids and potential role in lipid peroxidation 总被引:5,自引:0,他引:5
Previous studies documented the abnormal association of heme and heme proteins with the sickle RBC membrane. We have now examined RBC ghosts and inside-out membranes (IOM) for the presence of nonheme iron as detected by its formation of a colored complex with ferrozine. Sickle ghosts have 33.8 +/- 18.2 nmol nonheme iron/mg membrane protein, and sickle IOM have 4.3 +/- 3.0 nmol/mg. In contrast, normal RBC ghosts and IOM have no detectable nonheme iron. The combination of heme and nonheme iron in sickle IOM averages nine times the amount of membrane- associated iron in normal IOM. Kinetics of the ferrozine reaction show that some of this nonheme iron on IOM reacts slowly and is probably in the form of ferritin, but most (72% +/- 18%) reacts rapidly and is in the form of some other biologic chelate. The latter iron compartment is removed by deferoxamine and by treatment of IOM with phospholipase D, which suggests that it represents an abnormal association of iron with polar head groups of aminophospholipids. The biologic feasibility of such a chelate was demonstrated by using an admixture of iron with model liposomes. Even in the presence of tenfold excess adenosine diphosphate, iron partitions readily into phosphatidylserine liposomes; there is no detectable association with phosphatidylcholine liposomes. To examine the bioavailability of membrane iron, we admixed membranes and t-butylhydroperoxide and found that sickle membranes show a tenfold greater peroxidation response than do normal membranes. This is not due simply to a deficiency of vitamin E, and this is profoundly inhibited by deferoxamine. Thus, while thiol oxidation in sickle membranes previously was shown to correlate with heme iron, the present data suggest that lipid peroxidation is related to nonheme iron. In control studies, we did not find this pathologic association of nonferritin, nonheme iron with IOM prepared from sickle trait, high-reticulocyte, postsplenectomy, or iron-overloaded individuals. These data provide additional support for the concept that iron decompartmentalization is a characteristic of sickle RBCs. 相似文献
4.
5.
P. E. Lønning M. Dowsett A. Jones D. Ekse S. Jacobs F. McNeil D. C. Johannessen T. J. Powles 《Breast cancer research and treatment》1992,23(1-2):57-62
Summary The clinical and biochemical effects of combined treatment with the two aromatase inhibitors aminoglutethimide and 4-hydroxyandrostenedione were evaluated in 10 patients suffering from advanced breast cancer. All patients had become resistant to treatment with one of the drugs before having combined treatment. Seven patients progressing on 4-hydroxyandrostenedione who had aminoglutethimide added to their treatment and achieved a further suppression of plasma oestradiol by a mean of 40.0% (p<0.05). Plasma oestrone was suppressed by a mean of 40.6% (p<0.025) and plasma oestrone sulphate was suppressed by a mean of 63.6% (p<0.025). Two of the patients, neither of whom had responded to 4-hydroxyandrostenedione alone, experienced objective tumour regression when aminoglutethimide was given in concert. Three patients progressing on aminoglutethimide who had 4-hydroxyandrostenedione added showed no further suppression of their plasma oestrogen levels, and no tumour regression was observed. These findings suggest a dose-response relationship between plasma oestrogen suppression at low postmenopausal levels and objective tumour response in breast cancer. 相似文献
6.
F. A. MacNeill S. Jacobs M. Dowsett P. E. Lonning T. J. Powles 《Cancer chemotherapy and pharmacology》1995,36(3):249-254
This study investigated the influence of the aromatase inhibitor 4-hydroxyandrostenedione (4OHA, formestane), given orally, on peripheral aromatase activity and plasma oestradiol (E
2) levels in post-menopausal women with advanced breast cancer. The aim was to establish whether an optimal dose could be identified that had a pharmacological effectiveness comparable with that of parenteral 4OHA. A total of 13 post-menopausal women were studied before treatment and after a minimum of 4 weeks on treatment with one or more of the following doses: 125 mg once daily (od), 125 mg b.i.d. (bd) and 250 mg od. In all, seven aromatase studied were performed at 125 mg od; four, at 125 mg bd; and ten, at 250 mg od. Three patients were studied at all doses. E2 was measured concurrently and was available at all dose increments for seven patients. Given at doses of 125 mg od, 125 mg bd and 250 mg od, treatment with formestane inhibited in vivo aromatisation by 62.3%±9.5%, 70.0%±5.1% and 57.3%±5.3%, respectively (mean±SEM). Corresponding values for plasma E2 suppression were 30.7%±6.5%, 43.4%±4.5% and 42.9%±6.7%, respectively. Thus, apart from a somewhat better suppression of plasma E2 levels by the two higher doses as compared with 125 mg od, no significant difference in the degree of aromatase inhibition or plasma E2 suppression was observed. The suppression of E2 by oral 4OHA at 125 mg bd or 250 mg od approaches that achieved by the recommended parenteral schedule of 250 mg fortnightly, but inhibition of aromatase at this dose was substantially inferior. The findings are consistent with a hypothesis that 4OHA given orally may cause substantial plasma oestrogen suppression during part of the day, but neither the od nor the bd regimens investigated in the present study were capable of producing optimal aromatase inhibition. 相似文献
7.
8.
9.
Michael Bilous Mitch Dowsett Wedad Hanna Jorma Isola Annette Lebeau Aberlardo Moreno Frédérique Penault-Llorca Josef Rüschoff Gorana Tomasic Marc van de Vijver 《Modern pathology》2003,16(2):173-182
Knowledge of HER2 status is a prerequisite when considering a patient's eligibility for Herceptin (trastuzumab) therapy. Accurate assessment of HER2 status is essential to ensure that all patients who may benefit from Herceptin are correctly identified. There are several assays available to determine HER2 status: the most common in routine clinical practice are immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Various factors can affect the results achieved with these assays, including the assay antibody/probe, the methodology and the experience of personnel. Many countries have implemented national testing guidelines in an attempt to standardize testing procedures and make results more accurate. These guidelines vary in the level of detail and the number of recommendations. This review looks at areas of consensus between the different national testing guidelines and highlights where errors may arise during the testing procedure. The key point underlined by this review is that whatever method is used to test for HER2 status, the technology must be validated first, and there must be regular internal and external quality control and quality assurance procedures. 相似文献
10.
This study analyses the influence of female and male patient age and human
menopausal gonadotrophin (HMG) requirements on clinical pregnancy rates and
live birth rates with ovulation stimulation using HMG in combination with
intrauterine insemination (IUI). In this study, 363 consecutive HMG/IUI
treatment cycles in 184 patients carried out at a university fertility
centre were analysed in a retrospective fashion. The main outcomes measured
were clinical pregnancy rates and live birth rates. Increased female
partner age (> or = 35) and male partner age (> or = 40) were found
to negatively influence pregnancy rates with HMG/ IUI therapy. In addition,
this study demonstrated a critical threshold of HMG requirements beyond
which pregnancy did not occur. No pregnancies occurred in treatment cycles
requiring > 25 ampoules (1875 IU) of menotrophins to achieve follicular
maturity, irrespective of patient age. In conclusion, female partner age,
male partner age, and HMG requirements all significantly influence
pregnancy rates with HMG/IUI therapy.
相似文献